OrbiMed’s Eli Lilly LLY Stock Holding History

OrbiMed’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,000	Closed	-$4.85M	–	124
2022 Q3	$4.85M	Buy	+15,000	New	+$4.75M	0.09%	105
2017 Q1	–	Sell	-150,000	Closed	-$11M	–	140
2016 Q4	$11M	Sell	150,000 -100,000	-40%	-$7.45M	0.14%	90
2016 Q3	$20.1M	Buy	+250,000	New	+$20M	0.23%	75
2013 Q3	–	Sell	-100,000	Closed	-$4.91M	–	129
2013 Q2	$4.91M	Buy	+100,000	New	+$5.44M	0.1%	101

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed's LLY Position: Q2 2026 in Review

OrbiMed increased its Eli Lilly (LLY) stake by 8.9% in Q2 2026, buying an estimated $21.6M and bringing the position to 257,900 shares worth $309M. The position accounts for 5.73% of the portfolio, ranked #3.

OrbiMed first reported a position in LLY in Q1 2014 and has held it in 27 quarters since. The position peaked at $324M in Q4 2025. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

OrbiMed held 257,900 shares of Eli Lilly worth $309M as of Q2 2026.
OrbiMed bought 21,100 Eli Lilly shares in Q2 2026, an estimated $21.6M.
Eli Lilly made up 5.73% of OrbiMed's portfolio in Q2 2026, its #3 holding.
OrbiMed first reported a position in Eli Lilly in Q1 2014 and has held it in 27 quarters since.
OrbiMed's Eli Lilly position peaked at $324M in Q4 2025.
4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.